Healthcare Logic for Growth – Détails, épisodes et analyse

Détails du podcast

Informations techniques et générales issues du flux RSS du podcast.

Healthcare Logic for Growth

Eric Marr

Forme & Santé

Fréquence : 1 épisode/7j. Total Éps: 18

Actionable Insights and Go-Forward-Strategies for Hospitals, Clinics, Home Health, and Emerging Healthcare CompaniesWelcome to Healthcare Logic for Growth, the podcast from Life Science Logic where clinical breakthroughs meet commercial reality, where hospitals near-term challenges are discussed and translate into keeping the doors open, where healthcare leadership and their team can discover a revenue architecture that drives and sustains growth. Hosted by Eric Marr, this show is for the builders - founders, executives, clinicians, and innovators across home health, clinics, pharma, biotech, medtech, digital health, health systems, and rural hospitals. Each week, we break down the logic behind real healthcare growth. Not just the science - but the strategy. We explore go-to-market plays, market intelligence, and practical frameworks for navigating healthcare’s unique complexity. From ideation to clinical application to commercialization and adoption, we share hard-earned lessons from ...

Lire plusRéduire

Site

RSS

Apple

Classements récents

Dernières positions dans les classements Apple Podcasts et Spotify.

Apple Podcasts

🇺🇸 États-Unis - medicine
29/08/2026
#41
🇺🇸 États-Unis - medicine
28/08/2026
#39
🇺🇸 États-Unis - medicine
27/08/2026
#57
🇺🇸 États-Unis - medicine
26/08/2026
#55

Liens partagés entre épisodes et podcasts

Liens présents dans les descriptions d'épisodes et autres podcasts les utilisant également.

https://lifesciencelogic.com/
32 partages
https://www.himss.org/
2 partages
https://rockhealth.com/
2 partages

https://open.spotify.com/show/1YSwyajbIWDkVWwrIPM1j3
4 partages

https://www.youtube.com/@HealthcareLogicforGrowth
4 partages

Qualité et score du flux RSS

Évaluation technique de la qualité et de la structure du flux RSS.

Qualité du flux RSS

À améliorer

Score global : 62%

Historique des publications

Répartition mensuelle des publications d'épisodes au fil des années.

Year

Derniers épisodes publiés

Liste des épisodes récents, avec titres, durées et descriptions.

From Innovation to Revenue: How Healthcare Startups Turn a Great Product Into a Real Business

Épisode 9

lundi 15 juin 2026 • Durée 28:27

Healthcare is full of great products that never became great businesses. In this first episode of the Healthcare Startup Revenue Series, we break down 4 of the structural barriers that accelerate performance:

Buyer vs. user separation
Long purchasing cycles
The evidence requirement
Economic model misalignment

Whether you’re still in your first year of commercial activity or stuck at early customers and unable to scale, this episode gives you a foundation to consider.

Sources Referenced:

Rock Health Digital Health Funding Report - https://rockhealth.com/
HIMSS Healthcare Procurement Stakeholder Research - https://www.himss.org/
Health Care Transformation Task Force - Value-Based Care Contracting Frameworks - https://hcttf.org/

About Life Science Logic:

Life Science Logic helps hospitals, HHAs, healthcare associations, small life science and healthcare companies go to market smarter, not more expensively. We combine commercial strategy, competitive intelligence, and planning with a disciplined, cost-conscious approach - delivering the rigor of a top-tier consultancy without the expanded overhead. The result? Our clients cut unnecessary spending, improve commercial efficiency, and give better performance earlier.

Ready to spend less and perform better? Learn more at https://lifesciencelogic.com/ or reach us at Eric@lifesciencelogic.com.

Lire plusRéduire

CMS Just Changed the Playbook for GLP-1...Consider the Following

Épisode 8

lundi 8 juin 2026 • Durée 28:05

On May 1, 2026, the CMS BALANCE Model went live - opening the door for Medicaid agencies to begin enrolling in a new federal framework that expands GLP-1 coverage for obesity and metabolic disease. The Medicare GLP-1 Bridge follows on July 1st, giving Medicare Part D beneficiaries access to these drugs at $50 per month. Most of the conversation has focused on Novo Nordisk and Eli Lilly. This episode is for everyone else. We break down what BALANCE actually does, what the commercial ecosystem around it looks like for small pharma, biotech, digital health companies, home health agencies, and hospitals - and five specific actions you should be taking right now.

Sources Referenced in This Episode:

KFF - 'What to Know About the BALANCE Model for GLP-1s in Medicare and Medicaid and the Medicare GLP-1 Bridge' - Updated May 11, 2026
CMS Innovation Center - BALANCE Model Official Page and Implementation Timeline - cms.gov
CMS - 'Innovation Insight: Affordability of GLP-1s Takes Next Step with BALANCE Model RFAs' - March 9, 2026
Eli Lilly - Updated Statement on CMMI BALANCE Model and Medicare GLP-1 Bridge - March 2026
Fierce Healthcare - 'CMS Launching Payment Model to Boost Access to GLP-1s in Medicaid, Part D' - December 2025
IQVIA - 'Outlook for Obesity in 2026: From Consolidation to Acceleration' - January 2026
MMM Online - '2026 Is the Year GLP-1s Grow Up' - February 2026
AJMC - 'MFN Drug Pricing Proposal Raises Questions Around Access, Innovation, and Commercial Coverage' - May 22, 2026

About Life Science Logic:

Life Science Logic is a commercial strategy consultancy serving small life science, healthcare companies, and healthcare investors. We help founders and operators navigate go-to-market strategy, competitive intelligence, and commercial planning with the clarity and rigor that early-stage companies deserve and need. Learn more at https://lifesciencelogic.com/ or reach me at Eric@lifesciencelogic.com.

The Pilot Era Is Over - AI in Healthcare Has Crossed Into Real ROI, and Small Companies Are Running Out of Time to Catch Up

Épisode 7

lundi 1 juin 2026 • Durée 40:53

Healthcare is deploying AI tools at more than twice the rate of the broader economy — and for the first time at meaningful scale, the ROI is real and documented. In this episode, we unpack the NVIDIA State of AI in Healthcare 2026 survey and this week's Healthcare IT News report on AI payment alignment to answer the question every small healthcare company is quietly asking: what does the AI inflection point actually mean for my business right now? We cover three real-world scenarios across six audience segments — hospitals, home health agencies, digital health startups, pharma, biotech, and healthcare associations — and close with six specific actions you can take this week.

Links:

NVIDIA -'State of AI in Healthcare and Life Sciences: 2026 Trends' -February 2026
Healthcare IT News - 'Realizing the full value of AI in healthcare will require better alignment between payment models, regulatory expectations and outcomes' -May 21, 2026
Healthcare Dive - 'Top Healthcare AI Trends in 2026' -January 2026
BCG/BCG X -'How AI Agents and Tech Will Transform Health Care in 2026' - March 2026
Wolters Kluwer -'2026 Healthcare AI Trends: Insights from Experts' -December 2025
Chief Healthcare Executive -'AI in Health Care: 26 Leaders Offer Predictions for 2026' - January 2026
Bipartisan Policy Center - 'FDA Oversight: Understanding the Regulation of Health AI Tools' - March 2026
Precedence Research - AI in Healthcare Market Size Forecast - November 2025

About Life Science Logic:

The Medicaid Clock Is Already Ticking - What Every Small Healthcare Company Needs to Know Right Now

Épisode 6

lundi 25 mai 2026 • Durée 23:44

On May 1st, 2026, Nebraska became the first state in the country to enforce Medicaid work requirements under the One Big Beautiful Bill Act - the sweeping federal law that includes nearly a trillion dollars in Medicaid cuts over ten years. Montana goes live July 1st. Iowa in December. And 43 states are federally required to follow by January 1st, 2027. In this episode, we break down what this means for small life science and healthcare companies, why the 2027 framing is the wrong planning frame, and five specific steps you should be taking right now to protect your revenue model and your commercial strategy.

Sources Referenced in This Episode:

NPR - 'It's Day 1 of Medicaid Work Requirements in Nebraska,' May 1, 2026
KFF - 'An Early Look at Policy Decisions as States Get Ready to Implement Work Requirements,' May 2026
GoodRx Health - 'New Medicaid Work Requirements (2026): What to Know,' May 2026
AJMC - 'Medicaid Work Requirements Set to Leave Millions Without Insurance,' May 2026
Becker's Hospital Review - 'Hospitals Brace for New Wave of Federal Cuts,' April 2026
Center on Budget and Policy Priorities (CBPP) - 'States Need More Time to Prepare,' April 2026
KFF - 'How Might Federal Medicaid Cuts Affect Rural Areas?' September 2025
Fierce Healthcare - '2026 Outlook: The Domino Effect of Medicaid Cuts,' March 2026

About Life Science Logic:

The FDA Just Changed the Rules on Coverage - What Early-Stage Companies Need to Know.

Épisode 4

lundi 18 mai 2026 • Durée 14:37

On April 23, 2026, the FDA and CMS announced the RAPID coverage pathway - a new program designed to cut the historically long gap between FDA device authorization and Medicare coverage from a year or more down to as little as two months. For early-stage life science device companies, this changes the commercial math.

In this episode, we break down exactly what RAPID is, who qualifies, what it means for your launch strategy, and five specific steps you should be taking right now.

Determine your eligibility right now. If you have or are pursuing Breakthrough Device designation for a Class II or Class III device with a significant Medicare-age patient population, RAPID may apply to you.
Audit your IDE study design immediately. The RAPID pathway requires that your clinical outcomes be agreed upon by both FDA and CMS in advance. If your current study design was built solely around FDA's evidentiary requirements, you may have a gap.
Request a CMS engagement meeting. CMS has committed to early and frequent engagement with RAPID-eligible device companies during development. That is not a formality - it is a strategic resource built into the pathway.
Update your commercial launch model. If you have been modeling a one-to-two year gap between FDA authorization and Medicare coverage, and RAPID applies to your device, your timeline assumptions are out of date.
Engage the public comment process. When the RAPID proposed procedural notice hits the Federal Register, you will have 60 days to submit comments.

Sources Referenced in This Episode:

CMS.gov - RAPID Coverage Pathway Press Release, April 23, 2026
FDA.gov - Joint CMS/FDA Announcement, April 23, 2026
Foley Hoag LLP - RAPID Pathway Legal Analysis, April 2026
Healthcare Dive - 'CMS, FDA unveil speedier Medicare coverage pathway,' April 23, 2026
STAT News - 'CMS, FDA propose new, faster coverage for breakthrough devices,' April 23, 2026
Arnold & Porter - Regulatory & Reimbursement Analysis, April 2026

Biotech in 2026: The Capital, Clinical, and Commercial Triple Threat

Épisode 3

lundi 11 mai 2026 • Durée 13:57

Biotech in 2026 is operating inside a Triple Threat. In this episode, we break down the three forces hitting simultaneously: capital pressure that now demands commercial readiness alongside clinical proof, clinical complexity that has turned trial design into a commercial decision, and commercial infrastructure gaps that show up at the worst possible moment - right when you need them most.

If you're leading an early-stage biotech, preparing for a Series B, or building out your first commercial team, this episode gives you an honest picture of the landscape and three clear actions you can take right now.

WHY THIS MATTERS

The playbook that worked three years ago no longer applies. Capital is concentrating at later stages and investors are asking commercial questions earlier. Payers are demanding evidence that gets built into trial design - not bolted on after approval. And the gap between FDA approval and commercial success has not gotten any shorter.

What's different in 2026 is that these three pressures are compounding each other. A weak commercial story makes fundraising harder. A misaligned trial design creates payer problems at launch. And a company that hasn't built commercial infrastructure in parallel with clinical development finds itself scrambling when the window opens. This episode is about seeing all three threats clearly - and acting on them now.

WHAT WE COVER

The 2026 biotech landscape - what's changed and what hasn't
Threat 1: Capital Pressure - why investors now require commercial readiness alongside clinical proof
Threat 2: Clinical Complexity - why trial design is now a commercial decision, not just a regulatory one
Threat 3: Commercial Readiness - the infrastructure problem that shows up at the worst possible time
The Myth/Misconception: 'We'll figure out commercial after approval' - and why that window is now closed
How the three threats compound each other - and what that means for your planning horizon

YOUR GO FORWARD STRATEGY — 3 ACTIONS FROM THIS EPISODE

The Honest State of Early-Stage Life Science in 2026: What Every Biotech, Pharma, MedTech, and Digital Health Company Is Really Up Against

Saison 1 · Épisode 1

lundi 4 mai 2026 • Durée 17:02

In this opening episode of the Early-Stage Life Science series, host Eric delivers an honest 30,000-foot assessment of what early-stage life science companies are up against in 2026. Not the headline version. The operational reality.

WHY THIS EPISODE MATTERS

The life sciences landscape looks strong from the outside - a recovering biotech index, active M&A, and AI transforming drug discovery at a real pace. But underneath those headlines, the environment for early-stage companies has quietly gotten harder.

Capital is concentrating at later stages. The regulatory and reimbursement infrastructure hasn't gotten simpler. NIH funding pullbacks are creating upstream pressure that will shape the pipeline for years. The companies that succeed in this environment are the ones who see it clearly - not the ones running on optimism alone.

This episode gives you that clear view - and a practical starting point for building commercial strategy that holds up under the pressure of 2026.

WHAT WE COVER

The 2026 Landscape - Where the macro environment really stands - and why the operational reality for early-stage companies doesn't match the headlines.
The Commercial Strategy Gap - Why treating commercial strategy as something that happens after the science is done is one of the most costly mistakes in early-stage life science - and what parallel-track development looks like.
Capital Efficiency Under Pressure - How to connect every dollar to a fundable milestone - and why capital discipline has become a commercial strategy in itself.
The Payer and Reimbursement Wall - FDA approval doesn’t equal market access. What it takes to build a payer strategy that works - and why you need to start years before launch.
Talent and Team Building - Why the talent you need most is the hardest to attract at an early stage - and how the companies winning in 2026 are approaching it proactively.
Communication and Visibility - Why a company with strong science and low external presence is leaving relationships and resources on the table - and how to fix it before you need something from the market.

Welcome to 'Healthcare Logic for Growth.'

vendredi 1 mai 2026 • Durée 02:20

Actionable Insights and Go-Forward-Strategies for Hospitals, Clinics, Home Health, and Emerging Healthcare Companies

Welcome to Healthcare Logic for Growth, the podcast from Life Science Logic where clinical breakthroughs meet commercial reality, where hospitals near-term challenges are discussed and translate into keeping the doors open, where healthcare leadership and their team can discover a revenue architecture that drives and sustains growth. Hosted by Eric Marr, this show is for the builders - founders, executives, clinicians, and innovators across home health, clinics, pharma, biotech, medtech, digital health, health systems, and rural hospitals. Each week, we break down the logic behind real healthcare growth. Not just the science - but the strategy. We explore go-to-market plays, market intelligence, and practical frameworks for navigating healthcare’s unique complexity. From ideation to clinical application to commercialization and adoption, we share hard-earned lessons from both failures and wins.

CONNECT

Website: https://lifesciencelogic.com/
Email: Eric@lifesciencelogic.com

Lire plusRéduire

Priced to Win - How Small Life Science Companies Turn the MFN Drug Pricing Disruption Into a Commercial Advantage

Épisode 10

lundi 22 juin 2026 • Durée 28:07

The MFN drug pricing framework - what began as voluntary agreements with sixteen of the largest pharmaceutical companies - is now moving toward mandatory rules that will reach smaller biotechs and pharma companies. At the same time, a 100% pharmaceutical tariff takes effect September 29th for smaller manufacturers, with a lower 20% rate available only to companies that have engaged the MFN framework and filed domestic manufacturing plans.

BIO International opens at the same time of this published episode, June 22nd. So, in this episode, we flip the script: instead of treating MFN as a threat, we show small life science companies how to turn it into a commercial advantage - with five specific actions you can take starting this week.

Sources Referenced in This Episode:

Skadden Arps — "MFN Drug Pricing and Impact on International Life Sciences Licensing Deals" — June 1, 2026

BioTech Briefings / Gibson Dunn — "MFN Drug Pricing in 2026: Voluntary Deals Are Giving Way to Mandatory Rules" — March 2026

Clinical Leader — "U.S. Pharma Tariffs and MFN Become Law After April 2 Update" — April 2026

AJMC — "MFN Drug Pricing Proposal Raises Questions Around Access, Innovation, and Commercial Coverage" — June 2026

BioSpace — "Despite MFN Deals, Drug Pricing Will Dog Pharma Into 2026"

PharmExec — "What the Most Favored Nation Executive Order Means to Pharma Brands and Future Implications" — April 2026

BIO International Convention 2026 — San Diego, June 22–25, 2026 — convention.bio.org

White House Council of Economic Advisers — "Savings from Most-Favored-Nation Drug Pricing Policy" — May 2026

About Life Science Logic:

Life Science Logic is a commercial strategy consultancy serving small life science and healthcare companies. We help founders and operators build go-to-market strategies, competitive intelligence, and commercial plans with the clarity and rigor that early-stage companies deserve.

What Healthcare Startups Need to Do to Win - and Why So Many Fail

Épisode 11

lundi 29 juin 2026 • Durée 23:50

In this episode of Healthcare Logic for Growth, we break down what healthcare startups need to do to succeed - and why so many fail. We cover the five biggest success factors, including solving a real problem, proving outcomes, building the payment model early, fitting into clinical workflows, and scaling with trust. We also look at five common failure patterns, including weak validation, no reimbursement path, long sales cycles, poor workflow fit, and trust breakdowns.

We use real-world examples from Omada Health, Oshi Health, Zocdoc, Theranos, and Babylon Health to show what success and failure look like in practice. If you’re building, investing in, or marketing to healthcare startups, this episode is a practical guide to what actually matters. Key Topics - Why healthcare startups are different from consumer tech. - The five things a healthcare startup needs to do to succeed. - The five most common reasons healthcare startups fail. - Lessons from real companies with public-facing data. - Questions founders should ask to stay on track. - A go-forward strategy for building a durable healthcare company.

Sources Referenced in This Episode:

- AMA case study on Omada Health, highlighting evidence-based care, data-powered coaching, connected devices, and care coordination.

- Omada public platform information on outcomes and care delivery.

- AMA and related public materials on Oshi Health, including multidisciplinary GI care, outcomes, and cost savings.

- Zocdoc’s public milestone update on profitability, cash flow, provider growth, and business model improvements.

- STAT’s analysis of why healthcare startups fail, especially around reimbursement, pricing, and operational complexity.

- Public materials on Theranos’s failures and regulatory issues.

- Public reporting and analysis on Babylon Health’s collapse and reimbursement challenges.

About Life Science Logic:

Podcasts Similaires Basées sur le Contenu

Découvrez des podcasts liées à Healthcare Logic for Growth. Explorez des podcasts avec des thèmes, sujets, et formats similaires. Ces similarités sont calculées grâce à des données tangibles, pas d'extrapolations !